KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?

KRAS genotyping is mandatory in metastatic colorectal cancer treatment prior to undertaking antiepidermal growth factor receptor (EGFR) monoclonal antibody therapy. BRAF V600E mutation is often present in colorectal carcinoma with CpG island methylator phenotype and microsatellite instability. Curre...

Full description

Bibliographic Details
Main Authors: Nicolas Piton, Francesco Borrini, Antonio Bolognese, Aude Lamy, Jean-Christophe Sabourin
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2015/753903
id doaj-bdd539b56da74a7f9a9ba07d42bc7213
record_format Article
spelling doaj-bdd539b56da74a7f9a9ba07d42bc72132020-11-24T22:52:51ZengHindawi LimitedGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/753903753903KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?Nicolas Piton0Francesco Borrini1Antonio Bolognese2Aude Lamy3Jean-Christophe Sabourin4Laboratory of Cancer Genetics, Department of Pathology, Rouen University Hospital, 76031 Rouen, FranceDepartment of Surgery “Pietro Valdoni”, Rome University Hospital, La Sapienza, 00161 Rome, ItalyDepartment of Surgery “Pietro Valdoni”, Rome University Hospital, La Sapienza, 00161 Rome, ItalyLaboratory of Cancer Genetics, Department of Pathology, Rouen University Hospital, 76031 Rouen, FranceLaboratory of Cancer Genetics, Department of Pathology, Rouen University Hospital, 76031 Rouen, FranceKRAS genotyping is mandatory in metastatic colorectal cancer treatment prior to undertaking antiepidermal growth factor receptor (EGFR) monoclonal antibody therapy. BRAF V600E mutation is often present in colorectal carcinoma with CpG island methylator phenotype and microsatellite instability. Currently, KRAS and BRAF evaluation is based on molecular biology techniques such as SNaPshot or Sanger sequencing. As molecular testing is performed on formalin-fixed paraffin-embedded (FFPE) samples, immunodetection would appear to be an attractive alternative for detecting mutations. Thus, our objective was to assess the validity of KRAS and BRAF immunodetection of mutations compared with the genotyping reference method in colorectal adenocarcinoma. KRAS and BRAF genotyping was assessed by SNaPshot. A rabbit anti-human KRAS polyclonal antibody was tested on 33 FFPE colorectal tumor samples with known KRAS status. Additionally, a mouse anti-human BRAF monoclonal antibody was tested on 30 FFPE tumor samples with known BRAF status. KRAS immunostaining demonstrated both poor sensitivity (27%) and specificity (64%) in detecting KRAS mutation. Conversely, BRAF immunohistochemistry showed perfect sensitivity (100%) and specificity (100%) in detecting V600E mutation. Although molecular biology remains the reference method for detecting KRAS mutation, immunohistochemistry could be an attractive method for detecting BRAF V600E mutation in colorectal cancer.http://dx.doi.org/10.1155/2015/753903
collection DOAJ
language English
format Article
sources DOAJ
author Nicolas Piton
Francesco Borrini
Antonio Bolognese
Aude Lamy
Jean-Christophe Sabourin
spellingShingle Nicolas Piton
Francesco Borrini
Antonio Bolognese
Aude Lamy
Jean-Christophe Sabourin
KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
Gastroenterology Research and Practice
author_facet Nicolas Piton
Francesco Borrini
Antonio Bolognese
Aude Lamy
Jean-Christophe Sabourin
author_sort Nicolas Piton
title KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
title_short KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
title_full KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
title_fullStr KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
title_full_unstemmed KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
title_sort kras and braf mutation detection: is immunohistochemistry a possible alternative to molecular biology in colorectal cancer?
publisher Hindawi Limited
series Gastroenterology Research and Practice
issn 1687-6121
1687-630X
publishDate 2015-01-01
description KRAS genotyping is mandatory in metastatic colorectal cancer treatment prior to undertaking antiepidermal growth factor receptor (EGFR) monoclonal antibody therapy. BRAF V600E mutation is often present in colorectal carcinoma with CpG island methylator phenotype and microsatellite instability. Currently, KRAS and BRAF evaluation is based on molecular biology techniques such as SNaPshot or Sanger sequencing. As molecular testing is performed on formalin-fixed paraffin-embedded (FFPE) samples, immunodetection would appear to be an attractive alternative for detecting mutations. Thus, our objective was to assess the validity of KRAS and BRAF immunodetection of mutations compared with the genotyping reference method in colorectal adenocarcinoma. KRAS and BRAF genotyping was assessed by SNaPshot. A rabbit anti-human KRAS polyclonal antibody was tested on 33 FFPE colorectal tumor samples with known KRAS status. Additionally, a mouse anti-human BRAF monoclonal antibody was tested on 30 FFPE tumor samples with known BRAF status. KRAS immunostaining demonstrated both poor sensitivity (27%) and specificity (64%) in detecting KRAS mutation. Conversely, BRAF immunohistochemistry showed perfect sensitivity (100%) and specificity (100%) in detecting V600E mutation. Although molecular biology remains the reference method for detecting KRAS mutation, immunohistochemistry could be an attractive method for detecting BRAF V600E mutation in colorectal cancer.
url http://dx.doi.org/10.1155/2015/753903
work_keys_str_mv AT nicolaspiton krasandbrafmutationdetectionisimmunohistochemistryapossiblealternativetomolecularbiologyincolorectalcancer
AT francescoborrini krasandbrafmutationdetectionisimmunohistochemistryapossiblealternativetomolecularbiologyincolorectalcancer
AT antoniobolognese krasandbrafmutationdetectionisimmunohistochemistryapossiblealternativetomolecularbiologyincolorectalcancer
AT audelamy krasandbrafmutationdetectionisimmunohistochemistryapossiblealternativetomolecularbiologyincolorectalcancer
AT jeanchristophesabourin krasandbrafmutationdetectionisimmunohistochemistryapossiblealternativetomolecularbiologyincolorectalcancer
_version_ 1725664367997878272